Strategies to Potentiate Paracrine Therapeutic Efficacy of Mesenchymal Stem Cells in Inflammatory Diseases
Open Access
- 25 March 2021
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (7) , 3397
Abstract
Mesenchymal stem cells (MSCs) have been developed as cell therapeutics for various immune disorders using their immunoregulatory properties mainly exerted by their paracrine functions. However, variation among cells from different donors, as well as rapid clearance after transplantation have impaired the uniform efficacy of MSCs and limited their application. Recently, several strategies to overcome this limitation have been suggested and proven in pre-clinical settings. Therefore, in this review article, we will update the knowledge on bioengineering strategies to improve the immunomodulatory functions of MSCs, including genetic modification and physical engineering.Keywords
This publication has 161 references indexed in Scilit:
- IL1β Induces Mesenchymal Stem Cells Migration and Leucocyte Chemotaxis Through NF-κBStem Cell Reviews and Reports, 2012
- Identification of the earliest natural killer cell–committed progenitor in murine bone marrowBlood, 2011
- The Effect of Mesenchymal Stromal Cell–Hyaluronic Acid Hydrogel Constructs on Immunophenotype of MacrophagesTissue Engineering Part A, 2011
- Encapsulated mesenchymal stromal cells for in vivo transplantationBiotechnology and Bioengineering, 2011
- Inflammatory conditions affect gene expression and function of human adipose tissue-derived mesenchymal stem cellsClinical and Experimental Immunology, 2010
- T cells in multiple sclerosis and experimental autoimmune encephalomyelitisClinical and Experimental Immunology, 2010
- Aggregation of human mesenchymal stromal cells (MSCs) into 3D spheroids enhances their antiinflammatory propertiesProceedings of the National Academy of Sciences, 2010
- Allogeneic Mesenchymal Stem Cells for Treatment of Experimental Autoimmune EncephalomyelitisMolecular Therapy, 2009
- Pulmonary Passage is a Major Obstacle for Intravenous Stem Cell Delivery: The Pulmonary First-Pass EffectStem Cells and Development, 2009
- IFN‐γ activation of mesenchymal stem cells for treatment and prevention of graft versus host diseaseEuropean Journal of Immunology, 2008